alveolar lavage have positive results, and the mean time for isolation is nearly 1 week [10] . Rapid diagnosis by finding spherules in bronchoalveolar lavage on direct examination is possible in approximately two-thirds of cases. Others have reported demonstration of spherules in bronchoalveolar lavage in 30%-40% of patients with Coccidioides pneumonia [11] . Thus, although demonstration of spherules in respiratory secretions may provide a rapid diagnosis, at least one-third of cases may be missed by direct examination.
Serological testing for Coccidioides can be useful but may have negative results early in the infection and in immunosuppressed patients. The immunodiffusion test had positive results in 53% of immunosuppressed patients, compared with 73% of nonimmunosuppressed patients, and the complement fixation test had positive results in 67% and 75%, respectively [12] . The sensitivity of the immunodiffusion test may be enhanced by concentration of the serum [13] . In nonimmunosuppressed patients with acute Coccidioides pneumonia, the immunodiffusion test for IgM antibodies was positive in 1 of 10 patients, but results were positive in 9 of 10 patients after serum concentration [14] . Others noted seropositivity in approximately one-half of patients with Coccidioides pneumonia [10, 11] . Antigen detection could be useful for the early diagnosis of coccidioidomycosis. Antigenemia was noted in 56%-78% of patients with coccidioidomycosis in early studies [15] [16] [17] and in a more recent report [18] . We reported detection, using the Histoplasma antigen EIA, of a cross-reactive galactomannan antigen in the urine of 58% of patients with more-severe coccidioidomycosis [19] . We have endeavored to develop a specific Coccidioides antigen detection test and now evaluate its potential usefulness for the diagnosis of coccidioidomycosis.
PATIENTS AND METHODS
Vaccine preparation and immunization. Six patient isolates of C. immitis and C. posadasii were grown in brain-heart infusion broth at 37ЊC on a gyratory shaker (New Brunswick Scientific) for 72 h. Hyphae were removed by centrifugation, and the supernatant was decanted and combined with 3 volumes of absolute ethanol. Galactomannan was purified by immunoaffinity chromatography with use of concanavalin A, as described for preparation of Histoplasma galactomannan [20] . New Zealand white rabbits were immunized with galactomannan and formalin-killed mold, as described for production of antibodies to Histoplasma capsulatum [20] .
Calibration standards. Calibration standards were prepared from urine containing high levels of Coccidioides antigen, as described elsewhere [21] . Multiple dilutions of the standard were prepared, and the antigen content of each was determined by comparison with known concentrations of the purified galactomannan.
EIA. The MVista Coccidioides antigen EIA (MiraVista Diagnostics) was performed as reported elsewhere for the MVista Histoplasma antigen EIA (MiraVista Diagnostics) [20, 21] , except that microplates coated with rabbit anti-Coccidioides antibodies were used. Galactomannan attached to the capture antibody was detected with biotinylated rabbit anti-Coccidioides-detector antibody.
Clinical specimens. Urine specimens were available from 18 patients described elsewhere [19] and 6 additional patients with culture-proven cases of coccidioidomycosis from the clinical practices of the investigators. Controls included samples from patients with histoplasmosis (10 patients) or blastomycosis (10), which were left over from clinical testing; patients with paracoccidioidomycosis (8), provided by A. Restrepo, Colombia; patients with nonfungal infectious or noninfectious conditions for which Histoplasma antigen testing was ordered (50); patients with legionnaires disease (10), obtained from the Centers for Disease Control and Prevention; patients with Mycoplasma pneumonia (25), provided by J. Summersgill, University of Louisville; and healthy volunteers (75), purchased from SeraCare.
Statistical analysis. The cutoff for positivity was determined using receiver operating characteristic analysis.
RESULTS
Coccidioides and Histoplasma galactomannans were titrated using the Histoplasma and Coccidioides EIAs (figure 1). The lower limit of detection for Coccidioides galactomannan was 0.03 ng/ mL in the Coccidioides EIA, compared with 0.5 ng/mL in the Histoplasma antigen assay. The lower limit of detection for the Histoplasma galactomannan was 0.125 ng/mL in the Histoplasma EIA, compared with 8 ng/mL in the Coccidioides EIA. Thus, low concentrations of Coccidioides galactomannan (0.5 ng/mL) could be detected by the Histoplasma antigen EIA, which explains the high rate of cross-reactivity (58%) in patients with coccidioidomycosis [19] . Conversely, high concentrations of Histoplasma galactomannan (8 ng/mL) were required for cross-reactivity in the Coccidioides antigen EIA. Seven patients (29.2%) died of the infection. The diagnosis was based on positive culture results in 21 patients (87.5%), including 8 (33.3%) with positive results of culture samples obtained from extrapulmonary sites. Spherules were seen in respiratory specimens in 6 patients (25%). Serological test results were positive in 13 (54.2%) patients and were the basis for diagnosis in 3 (12.5%). Twenty-two urine specimens from 11 date were available for 7 patients, for a total of 46 specimens.
The cutoff for positivity was determined by testing 46 specimens from patients with coccidioidomycosis and 160 specimens from control individuals without systemic fungal infection. The area under the receiver operating characteristic curve was 0.940 (SE, 0.052; 95% CI, 0.90-0.97;
). With use P ! .001 of that cutoff, antigenuria was detected in 17 (70.8%; 95% CI, 50.8%-85.1%) of 24 patients with coccidioidomycosis and 1 (0.6%; 95% CI, 0.1%-3.4%) of 160 control individuals without fungal infections (figure 2). Under the assumption of a 5% prevalence of coccidioidomycosis among patients tested for Coccidioides antigen, assumed on the basis of histoplasmosis test results obtained at MiraVista Diagnostics, the positive predictive value is 85.7% and the negative predictive value is 98.5% among patients with more-severe forms of coccidioidomycosis.
Antigenuria was detected by the Histoplasma EIA in 14 (58.3%) of the patients with coccidioidomycosis (95% CI, 38.3%-75.5%), 2 of whom had negative results of the Coccidioides EIA. The first patient with a false-negative Coccidioides result was not immunocompromised and presented with pulmonary coccidioidomycosis, as determined by a positive serological test result; the Histoplasma antigen was weakly positive, at !0.6 ng/mL. The second patient was immunocompromised and had Coccidioides fungemia; the Histoplasma antigen concentration was 1.23 ng/mL. Neither patient had culture results positive for H. capsulatum or clinical findings suggestive of histoplasmosis. Overall, antigenuria was detected in 19 pa- tients (79.2%; 95% CI, 59.6%-90.8%) with use of either the Coccidioides or Histoplasma EIA.
Antigenuria was detected in 3 (10.7%) of 28 control individuals with other endemic mycoses (95% CI, 3.7%-27.2%), 2 of whom had histoplasmosis and 1 of whom had paracoccidioidomycosis (detected at 0.12 and 0.14 ng/mL and at 0.15 ng/mL, respectively). The Histoplasma antigen concentration was 139 ng/mL in 2 individuals and was 28.82 ng/mL in the third control individual, who had a positive Coccidioides EIA result.
Interassay reproducibility was determined by testing specimens from 5 patients 5 times. The results, expressed as mean ‫ע‬ SD (coefficient of variation), were as follows: 7.97 ‫ע‬ 1.02 ng/mL (12.7%), ng/mL (7.3%), ng/mL 2.62 ‫ע‬ 0.19 0.67 ‫ע‬ 0.04 (6.4%), ng/mL (12.3%), and ng/mL 0.48 ‫ע‬ 0.06 0.13 ‫ע‬ 0.01 (9.5%). Twenty positive specimens and 30 negative specimens were tested with 2 separate assays and were reproducible in all 50 tests.
DISCUSSION
The lower limit of detection for Coccidioides galactomannan was 0.03 ng/mL in the Coccidioides EIA, compared with 0.5 ng/ mL in the Histoplasma EIA, showing that the Coccidioides EIA was more sensitive for detection of antigenuria in patients with coccidioidomycosis than was the Histoplasma EIA. The sensitivity in patients with more-severe forms of coccidioidomycosis was 71% for the Coccidioides EIA, compared with 58% for the Histoplasma EIA.
An important caveat is that these findings should be applied only to patients with more-severe forms of coccidioidomycosis. More than three-quarters (79%) of the study patients were immunocompromised, nearly one-half (46%) had evidence of disseminated disease, almost one-third (30%) had fatal cases, and 87% had culture-positive specimens. Two patients with Coccidioides infection had positive results with the Histoplasma EIA but negative results with the Coccidioides EIA. This suggests that the antigenic makeup of individual Coccidioides strains may vary and that testing with both assays may be required to achieve the highest sensitivity. Coccidioides species-related specificity is unlikely, however, because the vaccine contained antigens from both C. immitis and C. posadasii, and antigenuria was demonstrated in patients from both Arizona and California.
The Coccidioides EIA is more specific for coccidioidomycosis than is the Histoplasma EIA. For example, Histoplasma galactomannan was detected only at concentrations of у8 ng/mL with use of the Coccidioides antigen EIA. Also, cross-reactions were noted in only 11% of specimens from patients with other endemic mycoses, which occurred in specimens containing very high Histoplasma antigen concentrations. Thus, cross-reactivity could be determined by testing the specimens with both EIAs.
Because of the favorable performance characteristics of the Coccidioides EIA described in this study, this test may be useful for rapid diagnosis of more-severe forms of coccidioidomycosis. These findings should not be applied to nonimmunocompromised patients with primary coccidioidomycosis or other forms of coccidioidomycosis that have not been evaluated. The turnaround time for the antigen test is 1 day in most cases. Although the EIA is highly specific, cross-reactions are possible in patients with other endemic mycoses. Concurrent testing with the Histoplasma EIA may detect some false-negative cases and identify cross-reactions caused by other endemic mycoses. Additional studies are needed to define the usefulness of the test in the various clinical forms of coccidioidomycosis, in patients with a variety of underlying diseases or no underlying disease, and in specimen types other than urine.
